COVID-19 antibodies in cystic fibrosis
Part of Digestive system, Genetic & congenital, Infections, Lungs & breathing clinical trials.
This study looks at how the body makes antibodies (proteins that fight infection) against COVID-19 in people with cystic fibrosis. It helps doctors understand how well your immune system responds to the virus or vaccine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cystic fibrosis (any age, any type).
- You are willing to give your consent to be in the study.
- You do not have a medical reason that makes a blood draw unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study examines a specific type of antibody (anti-annexin A2) that may develop during COVID-19 infection. By studying hospitalized COVID-19 patients, researchers hope to understand whether these antibodies are common and what role they might play in COVID-19 illness.
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This study tests if people with cystic fibrosis can collect sputum samples at home and mail them in, instead of coming to the clinic. It aims to make participation easier for patients.
This study looks for signs (markers) of bone thinning—called osteoporosis—in people with cystic fibrosis. Your participation may help researchers understand how osteoporosis develops in CF and whether a bone-strengthening medicine like denosumab could help, since some participants may need that medication.
This study measures how many healthcare workers have COVID antibodies (proof of past infection or immune response). Results may help estimate how widespread COVID exposure has been among hospital staff.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.